10 vials – 01/2027
International name: Dexketoprofen
Group affiliation: NSAIDs
Description of the active substance (INN): dexketoprofen
Description for trade name: Dexalgin
coated tablet, solution for intravenous and intramuscular administration
NSAIDs, a propionic acid derivative, has analgesic and antipyretic effects, the severity of the anti-inflammatory action – is negligible. The mechanism of action is associated with non-selective inhibition of TSOG1 and TSOG2 and impaired synthesis of Pg. The analgesic effect occurs within 30 minutes and lasts for 4-6 hours.
mild to moderate intensity of pain syndrome (various origins): acute and chronic diseases of the musculoskeletal system (including rheumatoid arthritis, osteoarthritis, low back pain), tuberculosis, toothache. It is intended for symptomatic therapy reduce pain and inflammation at the time of use, does not affect the progression of the disease.
Hypersensitivity, including to other NSAIDs, acute (including suspicion) and chronic gastrointestinal diseases (including history). Crohn’s disease, ulcerative colitis, peptic ulcer and 12 duodenal ulcer, bleeding (including gastrointestinal) and propensity to him, concomitant use of anticoagulants, asthma (including history), decompensated chronic heart failure, renal and / or hepatic insufficiency, complete or incomplete combination of bronchial asthma, recurrent nasal polyposis, and paranasal sinuses and intolerances ASA or others. NSAIDs (including history), the period after coronary artery bypass surgery, severe renal insufficiency (creatinine clearance less than 30 ml / min), progressive renal disease, severe hepatic impairment or active liver disease, confirmed by hyperkalemia, inflammatory diseases bowel, pregnancy, lactation.
Frequency: often – 1-10%, rarely – 0.1-1%, rarely – 0.01-0.1%, very rare – less than 0.01%. From the side of hematopoiesis: rarely – anemia, including aplastic and hemolytic, purpura, agranulocytosis, bone marrow hypoplasia, very rarely – neutropenia, thrombocytopenia. From the digestive system: often – nausea, vomiting, rare – abdominal pain, indigestion, diarrhea, constipation, bloody vomiting, dryness of the oral mucosa, rarely – erosive and ulcerative lesions of the gastrointestinal tract, including bleeding and perforation, anorexia, increased activity of ” liver “enzymes, jaundice, very rarely – liver dysfunction. From the nervous system: rarely – headache, dizziness, insomnia, drowsiness, rarely – paresthesia. From the sensory organs: rarely – blurred vision, rarely – ringing in the ears. From the CCC: rarely – decreased blood pressure, feeling of heat, redness of the skin, rarely – extrasystole, tachycardia, increased blood pressure, peripheral edema, thrombophlebitis of superficial veins. With the respiratory system: rarely – bradypnea, very rarely – bronchospasm. From the urinary system: rarely – polyuria, renal colic, very rarely – nephritis, nephrotic syndrome. From the reproductive system: rarely – dysmenorrhea, violation of the prostate gland. From the musculoskeletal system: rarely – muscle spasm, difficulty of movement in the joints. For the skin: rarely – dermatitis, rash, sweating, rarely – hives, acne, very rarely – Stevens-Johnson syndrome, Lyell’s syndrome, angioedema, allergic dermatitis, photosensitivity. On the part of metabolism: rarely – hyperglycemia, hypoglycemia, hypertriglyceridemia. From the laboratory parameters: rarely – ketonuria, proteinuria. Local reactions: often – pain at the injection site, rarely – an inflammatory reaction, hematoma, bleeding. Allergic reactions: very rarely – anaphylactic shock, swelling of the face. Other: rarely – hot flashes, chills, fatigue, aseptic meningitis occurring mainly in patients with SLE and mixed connective tissue disease.
Dosage and administration:
Inward (to accelerate absorption recommended intake for 30 minutes before eating), in 5.12 mg to 6 times per day (depending on the intensity of pain), or 25 mg to 3 times a day. The maximum daily dose – 75 mg in elderly patients, patients with impaired hepatic or renal function (slightly marked) – 50 mg. The course of treatment – no more than 3-5 days. V / m or / in (no more than 2 days, then move on to oral) 50 mg every 8-12 hours maximum daily dose -. 150 mg. In the elderly and in diseases of the liver or kidney dose should be reduced, the maximum daily dose – 50 mg.
Not intended for long-term treatment. In the event of dizziness and sleepiness should not engage in potentially hazardous activities that require povyennogo attention and speed of psychomotor reactions (including transport driving). To reduce the risk of adverse effects on the gastrointestinal tract to use the minimum effective dose as low as possible short course. May mask the symptoms of infectious diseases. Each ampoule contains a solution of 200 mg of ethanol.
When combined with other analgesic and anti-inflammatory drugs -. Strengthening activities. While the use of anticoagulants, drugs Li +, methotrexate, phenytoin, pentoxifylline, zidovudine, sulfonamides – increased side effects. It should be used with caution with diuretics, ACE inhibitors – the risk of acute renal failure in dehydrated patients, decrease the hypotensive effect of these drugs. It reduces the effect of antihypertensive drugs. It increases the nephrotoxicity of cyclosporin and tacrolimus. It increases the risk of bleeding in patients receiving thrombolytics. Drugs that block tubular secretion, reduce the renal tubular secretion of dexketoprofen that require dose adjustment of the latter. Increasing the concentration of cardiac glycosides in the plasma. Dexketoprofen should not be administered earlier than 8-12 days after mifepristone (the risk of reducing the effectiveness of the latter). It increases the risk of seizures in patients receiving high doses of ciprofloxacin. Pharmaceutical incompatible with dopamine, promethazine, pentazocine, pethidine, Hydroxyzine.
Description Deksalgin drug is not intended for purposes of treatment without the doctor.
|The purpose of the medication||Derivatives of propionic acid|